| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Glaukos Corporation$152.72
-2.35 (-1.52%)
C 50Pipeline Score MedTech · Commercial
Market Cap
7.06 B
EPS
-3.29
P/E Ratio
-
Value Trade
123.68 M
SEC Financials
Q1 2026Dilution Risk
Revenue
150.57 M
R&D Expenses
44.15 M
Operating CF
-12.53 M
Total Assets
893.33 M
Total Liabilities
222.40 M
Equity
670.93 M
D/E Ratio
12,345
-15.49 %
Week
-2.65 %
1 Month
3.35 %
3 Month
26.64 %
6 Month
58.99 %
5 Year
313.02 %
All Time
Cash Data
Cash Position
276.69 M
Monthly Burn
4.17 M
Runway
64.2 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
672.33 K
52 Week Range
73.16 - 148.11
% held by Insiders
4 %
% held by Institutions
100.82 %
Enterprise Value
6.89 B
Total Shares
58.72 M
Short %
7.41 %
Float Shares
55.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Glaukos Corporation
400Total events
2Upcoming
116Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 2
Event history 398
Jul 1, 2026
▲Product LaunchEpioxaApprovedPost-Market
Permanent J-code J2789 assigned for Epioxa, effective July 1, 2026
keratoconussource ↗
Jun 25, 2026
▲Enrollment CompleteGLK-321Trial
Completion of patient enrollment in Phase 2 study of GLK-321 for Demodex Blepharitis
Demodex Blepharitissource ↗
Jun 11, 2026
Jun 10, 2026
May 4, 2026
▲Enrollment CompleteTrial
Completed patient enrollment in Phase 3b study for iDose TRIO
Ocular Hypertension - Glaucomasource ↗
May 4, 2026
▲Topline ReadoutClinical Data
Initial results of Phase 2a clinical trial for iDose TREX show mean IOP reductions of 8.6-10.8 mmHg through Month 3
Ocular Hypertension - Glaucomasource ↗
Apr 15, 2026
▲Other Regulator MilestoneEpioxaApprovedEx-US Regulatory
Permanent J-code received for Epioxa
Apr 6, 2026
◆Oral PresentationPresentation
Multiple scientific abstracts presented at 2026 ASCRS Annual Meeting
Mar 2, 2026
▲First Patient DosediLutionTrial
Patient enrollment underway in Phase 2 clinical trial for Demodex blepharitis
Demodex Blepharitissource ↗
Mar 2, 2026
▲Enrollment CompleteGLK-401Trial
Patient enrollment complete in Phase 2a first-in-human clinical trial of IVT multi-kinase inhibitor
AMD, DME, RVOsource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $1.6B
Pipeline ValueValuation Signal
9
Drugs Scored0.8x
rNPV / MCap Top 76%
Small Cap (rank 220 of 911)
Percentile RankGlaukos Corporation carries a moderate pipeline score (50/100), with $2.5B risk-adjusted pipeline value, led by Gen 2 Travoprost Intracameral in Glaucoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gen 2 Travoprost Intracameral Small molecule | Glaucoma | Phase 3 | NCT07075718 | 44% | $870M | RECRUITING | 1,120 | STALLED | C (54) | Mar 1, 2032 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
iDose TR | glaucoma | Phase 2b/3 | 2024-11-15 | mean tfa concentrations: 3 months 5, 6 months 3.7, 12 months 5.6, 15 months 2, 18 months 2.2, 21 months 3.8, 24 months 3.3; avg amount of travoprost remaining: 24 months 16; adverse events: periorbital fat atrophy Up to 70% incidence, conjunctival hyperemia 30%-50% incidence, corneal endothelial cell loss Very low or no incidence, iris color change ~20% incidence Read More | Investor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate Read More | |
iDose TR | glaucoma | Phase 2b/3 | 2024-11-15 | mean tfa concentrations: 3 months 5, 6 months 3.7, 12 months 5.6, 15 months 2, 18 months 2.2, 21 months 3.8, 24 months 3.3; avg amount of travoprost remaining: 24 months 16; adverse events: periorbital fat atrophy Up to 70% incidence, conjunctival hyperemia 30%-50% incidence, corneal endothelial cell loss Very low or no incidence, iris color change ~20% incidence Read More | Investor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate Read More | |
iDose TR | glaucoma | Phase 2b/3 | 2024-11-15 | mean tfa concentrations: 3 months 5, 6 months 3.7, 12 months 5.6, 15 months 2, 18 months 2.2, 21 months 3.8, 24 months 3.3; avg amount of travoprost remaining: 24 months 16; adverse events: periorbital fat atrophy Up to 70% incidence, conjunctival hyperemia 30%-50% incidence, corneal endothelial cell loss Very low or no incidence, iris color change ~20% incidence Read More | Investor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GKOS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GKOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GKOS▼ -1.5%today
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Glaukos Corporation plans to release its second quarter 2026 financial results on July 29, 2026, after market close. The company, known for its ophthalmic therapies, will hold a conference call to discuss the results at 1:30 p.m. PT. This event is anticipated by investors as a potential indicator of the company's performance.
Read more →GKOSGlaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Glaukos has successfully completed patient enrollment for its Phase 2 study of GLK-321, aimed at treating Demodex blepharitis. This milestone marks a significant step in the development of potential new therapies for this condition. The study's progress reflects Glaukos' commitment to advancing eye care solutions.
Read more →GKOSGlaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation has announced its participation in upcoming investor conferences. The details regarding the specific conferences and the nature of their presentations have not been disclosed in the article. This participation may provide investors with insights into the company's future direction and performance.
Read more →GKOSDisclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are
The investor presentation from Glaukos Corporation (GKOS) outlines forward-looking statements regarding future activities and developments. The presentation emphasizes the company's commitment to innovation in chronic eye disease treatments, specifically their iDose TR and Epioxa therapies. However, management highlights several risks and uncertainties that could affect their operational outcomes and financial performance, including regulatory hurdles and manufacturing challenges. Glaukos continues to invest significantly in R&D, aiming to address unmet clinical needs in eye care.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs clewis@glaukos.com Glaukos Announces First Quarter 2026 Financial Results Aliso Viejo, CA –
Glaukos Corporation reported strong financial results for the first quarter of 2026, with record net sales of $150.6 million, representing a 41% increase compared to the previous year. U.S. Glaucoma sales saw an impressive rise of 58%, prompting the company to raise its sales guidance for the year. Despite these successes, Glaukos faced a loss from operations and increased expenses, highlighting ongoing financial challenges. The company remains focused on advancing its innovative pipeline, including products such as iDose TR and Epioxa.
Read more →GKOSGlaukos Announces First Quarter 2026 Financial Results
Glaukos Corporation reported record financial results for Q1 2026, with net sales reaching $150.6 million, a 41% increase from the previous year. The company raised its 2026 net sales guidance to between $620 million and $635 million. Despite the positive sales growth, Glaukos reported a net loss of $19.8 million, slightly higher than the previous year's loss. The company continues to focus on advancing its pipeline of novel therapies for chronic eye diseases.
Read more →GKOSGlaukos Receives Permanent J-code for Epioxa™
Glaukos Corporation announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent J-code, J2789, for its product Epioxa, effective July 1, 2026. This coding is expected to enhance market access and streamline billing for the treatment of keratoconus. Epioxa represents an innovative, non-invasive alternative to traditional corneal cross-linking procedures, promising improved patient outcomes.
Read more →GKOSGlaukos Announces the Release of its 2025 Sustainability Report
Glaukos has announced the release of its 2025 Sustainability Report. The report details the company's commitment to sustainable practices and environmental responsibility. Further specifics about the contents of the report were not provided in the announcement.
Read more →GKOSGlaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Glaukos Corporation has announced that it will release its financial results for the first quarter of 2026 after the market closes on April 29. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided during the release.
Read more →GKOSGlaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation will present several scientific abstracts at the upcoming 2026 ASCRS Annual Meeting. The event is significant for showcasing advancements in cataract and refractive surgery. Details regarding the specific abstracts and their implications for the field have not been disclosed.
Read more →GKOSInvestor Presentation MARCH 2026 ABOUT GLAUKOS 2 © 2026 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or develo
Glaukos Corporation is making strides in the treatment of chronic eye diseases with promising candidates in clinical trials. Their iLution platform for treating Demodex blepharitis has begun Phase 2 trials, while Epioxa is in line to become the first FDA-approved treatment for keratoconus with an epithelium-on approach. The company shows a solid financial position with a reported gross margin of 85% and no debt, supporting their pipeline growth. However, challenges remain in terms of patient compliance and awareness, as well as market reception for new therapies.
Read more →GKOS▲ +13.5%on this news
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
Glaukos Corporation reported strong financial results for Q4 and full year 2025, with net sales reaching $143.1 million in Q4, a 36% increase year-over-year. However, the company faced a significant operating loss of $139.9 million due to a one-time impairment charge. Despite these challenges, Glaukos remains optimistic about its growth prospects, projecting 2026 net sales between $600 million and $620 million.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results Aliso Viejo, CA
Glaukos Corporation has released its financial results for the fourth quarter and full year 2025, reporting strong net sales growth and a positive outlook for 2026. Despite a significant loss from operations and an impairment charge on its balance sheet, the company highlighted its robust pipeline of novel therapies and aims to achieve net sales of $600 million to $620 million in 2026. The fourth quarter net sales rose to $143.1 million, marking a 36% increase compared to the previous year. Glaukos' advancements in innovative ophthalmic treatments underscore its commitment to transforming care for patients with chronic eye diseases.
Read more →GKOSGlaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Glaukos Corporation announced FDA approval for an NDA supplement allowing the re-administration of iDose TR, a long-duration glaucoma treatment. This approval is based on clinical evidence supporting the safety of repeat use. The updated labeling provides physicians with more flexibility in managing glaucoma patients, enhancing treatment access for those in need.
Read more →GKOSGlaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Glaukos Corporation plans to release its fourth quarter and full year 2025 financial results on February 17, 2026. The announcement includes a conference call and webcast to discuss the results. The company continues to innovate in ophthalmic therapies, particularly for glaucoma and corneal disorders.
Read more →GKOS▼ -5.3%on this newsshared move
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
Glaukos Corporation announced preliminary, unaudited net sales for Q4 and full year 2025, reporting a 36% increase in Q4 sales and a 32% increase for the year. The company reaffirmed its 2026 revenue guidance of $600 million to $620 million. CEO Thomas Burns highlighted the company's successful execution and robust pipeline of novel therapies.
Read more →GKOSInvestor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net
Glaukos Corporation announced preliminary, unaudited net sales results for the fourth quarter and full year of 2025, indicating a strong performance with significant year-over-year increases. Q4 sales reached approximately $143 million, reflecting a 36% growth compared to the previous year, while total annual sales for 2025 are expected to be around $507 million, marking a 32% increase. The company also reaffirmed its 2026 revenue guidance, projecting net sales between $600 million and $620 million. However, the results are preliminary and subject to further revision, and potential risks to future sales and product commercialization were noted.
Read more →GKOS▲ +5.4%on this news
November 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate
Glaukos Corporation continues to advance its product pipeline with a focus on chronic eye diseases, including various glaucoma therapies and treatments for keratoconus. The company reported strong financial performance, with a gross margin of 84% for the third quarter of 2025 and no debt on its balance sheet. Key milestones include FDA approval for several products and advancements in clinical trials, signaling potential growth in the coming years. Glaukos aims to innovate treatment paradigms, particularly through its iLink therapy and dropless delivery systems.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Third Quarter 2025 Financial Results Aliso Viejo, CA
Glaukos Corporation announced its third quarter 2025 financial results, showcasing a 38% rise in net sales to $133.5 million compared to the prior year. The company reported improvements in gross margins and reduced operational losses, indicating effective management and a robust business strategy. Furthermore, Glaukos provided optimistic revenue guidance for 2025, estimating between $490 million and $495 million, and a preliminary range of $600 million to $620 million for 2026. Despite some increases in R&D expenses and operational losses, the overall financial performance reflects strong market execution and a promising pipeline of therapeutic innovations.
Read more →GKOSAugust 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wi
Glaukos Corporation continues to innovate in the field of chronic eye disease treatment with a diverse pipeline aimed at addressing glaucomas and keratoconus. As of 2Q 2025, the company reported strong financial performance with substantial gross margins and a healthy cash reserve. Key pipeline milestones include expected FDA approvals and advancements in their proprietary treatment technologies. The company aims to enhance patient care and compliance through new therapeutic options.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Second Quarter 2025 Financial Results Aliso Viejo, CA
Glaukos Corporation announced strong financial results for its second quarter of 2025, reporting net sales of $124.1 million, a 30% increase year-over-year. The company highlighted successful execution of strategic plans and advancements in its innovative pipeline of therapies for chronic eye diseases. Though expenses in selling and administrative areas rose, operational improvements led to a reduced net loss compared to the previous year's quarter. Glaukos ended the quarter with approximately $278.6 million in cash, indicating solid financial health as it navigates future opportunities and challenges.
Read more →GKOSMay 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
Glaukos Corporation presented its investor materials for May 2025, emphasizing its commitment to advancing science and technology in the treatment of chronic eye diseases. The company has reported solid financial performance, with a gross margin of 82% in the first quarter of 2025 and plans to further develop its pipeline, including therapies for glaucoma and keratoconus. Several key product approvals are anticipated, which could significantly impact the company's growth trajectory. However, uncertainties surrounding regulatory approvals remain a potential risk for the ongoing development of these therapies.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces First Quarter 2025 Financial Results Aliso Viejo, CA
Glaukos Corporation has reported its financial results for the first quarter of 2025, highlighting a 25% increase in net sales compared to the same period the previous year. The company experienced a gross margin of approximately 77% and reduced its loss from operations year-on-year. Despite the overall positive results, Glaukos still faced a net loss of $18.1 million and reported rising selling and administrative expenses. The company aims to maintain momentum with its innovative pipeline and has issued revenue guidance projecting net sales between $475 million and $485 million for 2025.
Read more →GKOS▲ +5.7%on this news
March 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wil
Glaukos Corporation provided insights into its strategic direction and product pipeline during a recent investor presentation. The company emphasizes its commitment to innovation in chronic eye disease management, reporting strong financial performance with an 82% gross margin. Key milestones for 2025 include advancing various products through clinical trials and regulatory processes. However, several therapies remain unapproved by the FDA, presenting potential challenges as they seek to enhance treatment options in the ophthalmic field.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results Aliso Viejo, CA
Glaukos Corporation has reported impressive financial results for the fourth quarter and full year 2024, with net sales reaching $105.5 million, a 28% increase year-over-year. The company attributed this success to the effective execution of its commercial and development plans, projecting revenue growth for 2025 between $475 million and $485 million. However, it noted an operating loss of $28.7 million in Q4 2024, reflecting ongoing challenges in managing expenses despite positive sales growth.
Read more →GKOSJanuary 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate w
Glaukos Corporation is emphasizing its commitment to innovation in treating chronic eye diseases. The company has a robust pipeline of products, including advancements in therapies targeting glaucoma and keratoconus, with several expected milestones by 2025. Financially, Glaukos reported a solid gross margin and strategic growth planning, but faces ongoing challenges with patient compliance and the need for FDA approvals for certain products.
Read more →GKOSInvestor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate
Glaukos Corporation presented its investor updates highlighting substantial progress in its glaucoma pipeline, particularly the iDose TR therapy, which has received FDA approval. The company is preparing for the commercial launch, emphasizing the significance of training and market access. Additionally, they plan to submit a New Drug Application for Epioxa, indicating ongoing commitment to developing treatments for chronic eye diseases. Their global sales performance and financial management have also been reported positively, reflecting their stability in the market.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Third Quarter 2024 Financial Results Aliso Viejo, CA
Glaukos Corporation announced its financial results for the third quarter of 2024, reporting net sales of $96.7 million, a 24% increase from the previous year. The company posted a non-GAAP net loss of $15.2 million, though this was an improvement from the $24.2 million loss reported in Q3 2023. Glaukos continues to develop its innovative product pipeline, including the recent launch of iDose TR designed for continuous glaucoma treatment. Confidence in future performance is reflected in the company's guidance of $377 million to $379 million in net sales for 2024.
Read more →GKOSNOTICE OF FULL REDEMPTION GLAUKOS CORPORATION 2.75% Convertible Senior Notes due 2027 CUSIP: 377322 AB8 NOTICE IS HEREBY GIVEN pursuant to Section 16.02 of the Indenture, dated as of
Glaukos Corporation announced the full redemption of its 2.75% Convertible Senior Notes due 2027, effective December 16, 2024. The redemption includes a principal amount of $57.5 million and the securities must be surrendered to receive the redemption price plus any accrued interest. Holders will also have the option to convert their notes into shares of common stock up until December 13, 2024. The notice outlines the procedures for redemption and conversion, as well as the responsibility of holders regarding tax certification.
Read more →GKOSInvestor Presentation August 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wi
Glaukos Corporation provided an overview of its performance and strategic directions in its August 2024 investor presentation. The company highlighted positive sales trends across its glaucoma franchise and advancements in its clinical pipeline, including FDA approval of the iDose TR for ocular hypertension. Additionally, the company detailed its operational efficiencies and the planned submission of a New Drug Application for the Epioxa product by the end of 2024, underlining its commitment to innovation in ophthalmic therapies. Glaukos is preparing to drive the global interventional glaucoma market further, suggesting a strong outlook for its future initiatives.
Read more →GKOSGLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Six Months Ended June 30
Glaukos Corporation reported its condensed consolidated statements of operations for the three and six months ended June 30, 2024. The company experienced an increase in net sales and gross profit compared to the prior year. However, it also reported a net loss that widened year-over-year, alongside rising operating expenses. Overall, while upper metrics show growth, the financial results indicate ongoing challenges with profitability.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Second Quarter 2024 Financial Results Aliso Viejo, CA
Glaukos Corporation (NYSE: GKOS) announced its financial results for the second quarter of 2024, posting a 19% increase in net sales, amounting to $95.7 million. Despite this growth, the company reported an increased operating loss and a wider net loss compared to the previous year. The company emphasizes advancements in its innovative pipeline aimed at improving patient outcomes for chronic eye diseases. The positive trends in sales contrast with rising operational costs, particularly in SG&A expenses.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% C
Glaukos Corporation announced that it has entered into agreements to exchange $230 million of its convertible senior notes for common stock. This transaction is set to close around June 25, 2024, pending customary conditions. The exchange aims to enhance the company's equity position as it continues to focus on the development of innovative ophthalmic therapies. However, the common stock involved has not been registered under the Securities Act, which presents some risks to investors, coupled with broader uncertainties affecting the company's operations.
Read more →GKOSInvestor Presentation May 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
Glaukos Corporation is pushing forward with their innovative treatments for chronic eye diseases, particularly focusing on Interventional Glaucoma. The company’s iDose TR product has been successfully launched, indicating strong initial sales and a robust commercial strategy. Advances in their clinical pipeline include ongoing trials for glaucoma and dry eye treatments, with plans to submit new drug applications to the FDA by the end of 2024. Overall, Glaukos positions itself as a leader in transforming eye care with its tech-driven solutions.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces First Quarter 2024 Financial Results Aliso Viejo, CA
Glaukos Corporation announced its financial results for the first quarter of 2024, reporting net sales of $85.6 million, a 16% increase compared to the previous year. The gross margin remained stable at approximately 76%. However, the company experienced a larger operational loss of $39.1 million and a widened net loss of $40.8 million. Despite these challenges, Glaukos has issued a revenue guidance for 2024, projecting net sales between $357 million and $365 million, indicating a positive outlook for continued growth.
Read more →GKOSInvestor Presentation February 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate
Glaukos Corporation is advancing its portfolio with significant developments in ocular therapies, particularly the iDose TR for interventional glaucoma, which has been successfully approved and is set for commercial launch. The company reported robust sales, efficient expense management, and comprehensive pipeline progress across various technologies. With the aim of pioneering advancements in glaucoma treatment, Glaukos plans to enhance global access and patient care for chronic eye diseases while navigating potential market and regulatory challenges.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results Aliso Viejo, CA
Glaukos Corporation reported its financial results for Q4 and the full year 2023, highlighting a revenue increase of 16% in Q4, reaching $82.4 million. Despite these gains, the company experienced a net loss of $36.8 million in Q4, and overall losses for the year rose to $134.7 million. The firm anticipates revenue guidance for 2024 between $350 million and $360 million, attributed to positive market momentum in ophthalmic therapies. The management expressed confidence moving into 2024, supported by a robust pipeline of innovative solutions in eye care.
Read more →GKOS▲ +5.5%on this news
Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net
Glaukos Corporation has announced its preliminary, unaudited net sales figures for the fourth quarter and full year of 2023, reporting expectations of over $81 million in Q4 and more than $313 million for the entire year. The company also reaffirmed its revenue guidance for 2024, estimating sales between $350 million and $360 million. Glaukos specializes in ophthalmic medical technologies and has been focusing on innovative treatments for glaucoma and other eye disorders.
Read more →GKOS▲ +25.4%on this news
Glaucoma: Stefanie Tuck (978) 390-1394 stefanie@jpa.com Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos
Glaukos Corporation has announced the FDA approval of its iDose TR, a travoprost intracameral implant indicated for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This innovative micro-invasive treatment aims to enhance patient adherence and reduce complications commonly associated with traditional topical medications. Phase 3 clinical trials demonstrated the iDose TR's effectiveness and favorable safety profile, leading to its approval for a single administration per eye. Glaukos plans to launch iDose TR commercially in early 2024 and has committed to charitable initiatives alongside its product introduction.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Third Quarter 2023 Financial Results Aliso Viejo, CA
Glaukos Corporation (NYSE: GKOS) announced its financial results for the third quarter of 2023, reporting a 10% increase in net sales to $78 million versus $71.3 million in the previous year. The company's gross margin remained steady at around 76%, though they registered increased losses from operations and higher SG&A expenses. Glaukos continues to advance its product pipeline aimed at improving care for patients with chronic eye diseases. Looking ahead, Glaukos expects net sales for 2023 to be between $307 million to $310 million.
Read more →GKOSInvestor Presentation August 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wi
Glaukos Corporation's August 2023 investor presentation highlighted encouraging results from the Phase 2a trial of its iLution dropless therapy for dry eye disease. The trial showed an improvement in tear film quality and significant completion rates without serious adverse events. However, there are still pending approvals for some of their therapies, notably the Epi-on treatment for keratoconus and ongoing concerns regarding the need for corneal transplants in severe cases of keratoconus. Overall, the company is positioned for future growth in the ophthalmology market with its evolving product pipeline.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Second Quarter 2023 Financial Results Aliso Viejo, CA
Glaukos Corporation has announced its financial results for the second quarter of 2023, reporting net sales of $80.4 million, a notable increase from $72.7 million in the previous year. The company highlighted its strong performance with double-digit growth reflecting successful commercial strategies and ongoing investments in its innovative pipeline. Despite the positive revenue growth, Glaukos also reported a net loss of $32.8 million, which requires attention as the company progresses. The firm expects its 2023 net sales to be within the range of $304 million to $308 million.
Read more →GKOSInvestor Presentation May 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
Glaukos Corporation recently presented promising results from its Phase 2a trial of iLution Dry Eye, showcasing high patient retention and favorable safety outcomes. Additionally, the Epi-on treatment for keratoconus demonstrated potential in halting disease progression but remains unapproved by the FDA. The trial outcomes enhance confidence in Glaukos's innovative therapies for ocular conditions, despite the need for regulatory approvals.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces First Quarter 2023 Financial Results Aliso Viejo, CA
Glaukos Corporation reported its first quarter 2023 financial results, showcasing a 9% increase in net sales to $73.9 million. The company announced a net loss of $34.6 million, contrasting sharply with a gain in the same quarter last year. Despite rising expenses in both SG&A and R&D, Glaukos expressed optimism due to a robust pipeline and solid growth indicators. Looking ahead, the company projects 2023 net sales to reach between $295 million and $300 million.
Read more →GKOSInvestor Presentation March 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wil
Glaukos Corporation presented updates on its ongoing clinical trials and product pipeline related to eye diseases. The company showcased promising results from its Phase 2a trial for the iLution Dry Eye therapy, which observed a significant improvement in tear break-up time and a reduction in blurred vision symptoms. Overall patient completion rate for the trial was impressive at 98%. Additionally, Glaukos highlighted its future strategies focusing on dropless therapies aimed at enhancing patient compliance and comfort.
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results Aliso Viejo, CA
Glaukos Corporation announced its financial results for the fourth quarter and full year of 2022, reporting a decline in net sales and an increase in operating losses compared to the previous year. Despite facing reimbursement challenges and rising operational costs, the company remains focused on advancing its pipeline of novel therapies for chronic eye diseases. Looking ahead, Glaukos projects a slight increase in net sales for 2023. The company concluded the fourth quarter with a cash reserve of approximately $360 million.
Read more →GKOSInvestor Presentation January 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate w
Glaukos Corporation's investor presentation highlighted promising early results from the iLution Dry Eye Phase 2A trial, showing safety and improvement in tear film quality. The company aims to address treatment gaps in various ophthalmic conditions with its dropless therapy platform. Additionally, Glaukos is expanding its pipeline, focusing on innovative therapies for keratoconus and retinal diseases, suggesting a strong growth potential in the evolving ophthalmic market.
Read more →GKOSInvestor Presentation NOVEMBER 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that
Potential target sites for iLution formulations 25 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM DISEASE STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS T
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2022 Financial Results Aliso Viejo, CA
Vice President, Investor Relations & Corporate Affairs Glaukos Corporation Announces Third Quarter 2022 Financial Results Aliso Viejo, CA - November 2, 2022 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapie
Read more →GKOS▲ +18.5%on this news
Investor Presentation SEPTEMBER 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments tha
Potential target sites for iLution formulations 25 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM DISEASE STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS T
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Second Quarter 2022 Financial Results Aliso Viejo, CA
Vice President, Investor Relations & Corporate Affairs Glaukos Corporation Announces Second Quarter 2022 Financial Results Aliso Viejo, CA - August 3, 2022 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies
Read more →GKOSInvestor Presentation MAY 2022 2 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect,
Investor Presentation MAY 2022 2 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are f
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2022 Financial Results San Clemente, CA
Vice President, Investor Relations & Corporate Affairs Glaukos Corporation Announces First Quarter 2022 Financial Results San Clemente, CA - May 4, 2022 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies fo
Read more →GKOSInvestor Presentation MARCH 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we
Potential target sites for iLution formulations 22 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM PATIENT STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS T
Read more →GKOSChris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results San Cl
Vice President, Investor Relations & Corporate Affairs Announces Fourth Quarter and Full Year 2021 CA - February 22, 2022 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c
Read more →GKOSCassandra Dump (619) 971-1887 Cassy@pascalecommunications.com Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.com Gl
Cassy@pascalecommunications.com Vice President, Investor Relations & Corporate Affairs Glaukos Announces Executive Leadership Changes San Clemente, CA - February 7, 2022 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on
Read more →GKOS▲ +10.8%on this news
Investor Presentation JANUARY 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that
Potential target sites for iLution formulations 22 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM PATIENT STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS T
Read more →GKOSChris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the
Sr. Director, Investor Relations & Corporate Strategy & Development Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director San Clemente, CA - December 20, 20
Read more →GKOSxA9; 2021 Glaukos Corporation Investor Relations Presentation NOVEMBER 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address
Eye Contact Lens. 2014;40(6):382-389. iLink is first and only FDA-approved corneal cross-linking procedure (CXL) that slows or halts progressive keratoconus Left untreated, 1 in 5 progressive keratoconus patients may require corneal transplant; more than half could need multiple
Read more →GKOSChris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2021 Financial Results San Clem
Sr. Director, Investor Relations & Corporate Strategy & Development Glaukos Corporation Announces Third Quarter 2021 Financial Results San Clemente, CA - November 4, 2021 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on
Read more →GKOSxA9; 2021 Glaukos Corporation August 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or development
Eye Contact Lens. 2014;40(6):382-389. iLink is first and only FDA- approved corneal cross-linking procedure (CXL) that slows or halts progressive keratoconus Left untreated, 1 in 5 progressive keratoconus patients may require corneal transplant; more than half could need multiple
Read more →GKOSChris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Second Quarter 2021 Financial Results San Cle
Sr. Director, Investor Relations & Corporate Strategy & Development Glaukos Corporation Announces Second Quarter 2021 Financial Results San Clemente, CA - August 5, 2021 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on n
Read more →GKOSChris Lewis Sr. Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2021 Financial Results San Cleme
Sr. Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces First Quarter 2021 Financial Results San Clemente, CA - May 5, 2021 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel
Read more →GKOSxA9; 2021 Glaukos Corporation March 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments
Of Inventory Stock-based Reversal of Employee Inventory Dev Tech Write-off Comp Exp on Restructuring Retention/ Fair Value Adj Intangibles & iStent Inject Replacement Expenses Family First FY2020 GAAP net of COVID E&O Reserves Awards Credits FY2020 Non-GAAP Gross Margin E&O rever
Read more →GKOSCassandra Dump (619) 971-1887 Cassy@pascalecommunications.com Investor Contact: Chris Lewis Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 clewis@glauk
Cassy@pascalecommunications.com Director, Investor Relations & Corporate Strategy & Development Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors San Clemente, CA - March 1, 2021 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Result
Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 Glaukos Corporation Announces Fourth Quarter and Full Year 2020 San Clemente, CA - February 25, 2021 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company foc
Read more →GKOSxA9; 2020 Glaukos Corporation 1 November 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or develop
J Cataract Refract Surg, 2015 ; 2 America, E.B.A.o., 2015 Eye Banking Statistical Report. 2016 ; 3 Rebenitsch, R.L., et al., The lifetime economic burden of keratoconus: a decision analysis using a markov model. Am J Ophthalmol, 2011 18 2020 Glaukos Corporation Epi-on Therapy Non
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2020 Financial Results San Clemente,
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Third Quarter 2020 Financial Results San Clemente, CA - November 5, 2020 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Second Quarter 2020 Financial Results San Clemente
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Second Quarter 2020 Financial Results San Clemente, CA - August 6, 2020 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel
Read more →GKOSFINANCIAL STATEMENTS OF AVEDRO Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Avedro, Inc. Opinion on the Financial Statements We have audited the accompanying b
STATEMENTS OF AVEDRO of Independent Registered Public Accounting Firm the Stockholders and the Board of Directors of Avedro, Inc. on the Financial Statements have audited the accompanying balance sheets of Avedro, Inc. (the "Company") as of December 31, 2018 and 2017, the re
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Proposed Private Offering of $200 Million of Conve
Director, Investor Relations, Corporate Strategy & Development Announces Proposed Private Offering of $200 Million of Convertible Senior Notes San Clemente, CA - June 8, 2020 - Glaukos Corporation (NYSE: GKOS) (the "Company" or "Glaukos"), an ophthalmic medical technology and
Read more →GKOSxA9; 2020 Glaukos Corporation 1 May 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments
Am J Ophthalmol, 2011 18 2020 Glaukos Corporation Epi-on Therapy Non-Invasive Therapy Offers Potential to Expand Keratoconus Treatment Population Designed to reduce treatment time and complexity; improves patient comfort and faster recovery; expected to drive increased willingnes
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2020 Financial Results San Clemente,
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces First Quarter 2020 Financial Results San Clemente, CA May 7, 2020 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapie
Read more →GKOSgkos_exh99_1 FOR IMMEDIATE RELEASE Investor Contact Chris Lewis Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clewis@glaukos.com Media Contact Cassandra Dump 619-971-1887 cassy@pascalecommun
Director, Investor Relations, Corporate Development & Strategy cassy@pascalecommunications.com Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020 San Clemente, CA April 9, 2020 Glaukos Corporation (NYSE: GKOS), an ophthalmi
Read more →GKOSInvestor Contact Chris Lewis Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clewis@glaukos.com Media Contact Cassandra Dump 619-971-1887 cassy@pascalecommunications.com
FOR IMMEDIATE RELEASE Investor Contact Chris Lewis Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clewis@glaukos.com Media Contact Cassandra Dump 619-971-1887 cassy@pascalecommunications.com Glaukos Provides COVID-19 Pandemic Update San Cl
Read more →GKOSxA9; 2020 Glaukos Corporation 1 March 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developmen
Am J Ophthalmol, 2011 18 2020 Glaukos Corporation Epi-on Therapy Non-Invasive Therapy Offers Potential to Expand Keratoconus Treatment Population Designed to reduce treatment time and complexity; improves patient comfort and faster recovery; expected to drive increased willingnes
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial Result
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Fourth Quarter and Full Year 2019 San Clemente, CA February 27, 2020 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel thera
Read more →GKOSxA9; 2020 Glaukos Corporation 1 January 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developm
Am J Ophthalmol, 2011 18 2020 Glaukos Corporation Epi-on Therapy Non-Invasive Therapy Offers Potential to Expand Keratoconus Treatment Population Designed to reduce treatment time and complexity; improves patient comfort and faster recovery; expected to drive increased willingnes
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Media Contact: Cassandra Dump 619-971-1887 cassy@pascalecommunications.com Glauk
Director, Investor Relations, Corporate Strategy & Development cassy@pascalecommunications.com Glaukos Completes Acquisition of Avedro, San Clemente, CA - November 21, 2019 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused
Read more →GKOSgkos_ex99_1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2019 Financial Results S
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Third Quarter 2019 Financial Results San Clemente, CA November 6, 2019 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel the
Read more →GKOSxA9; 2019 Glaukos Corporation 1 November 2019 Transforming Ophthalmology acquisition of 2 © 2019 Glaukos Corporation Use of Forward-Looking Statements This communication contains “forward-looking statements&#
Disclaimer 5 2019 Glaukos Corporation Creating Hybrid Pharma & Device Ophthalmic Leader GLAUKOS TO ACQUIRE AVEDRO Combines two highly complementary, hybrid pharma & device ophthalmic organizations Leverages Glaukos' proven market-building experience, global commercial scale and s
Read more →GKOSGlaukos and Avedro Announce Definitive Acquisition Agreement
-- Click here to rapidly navigate through this document Glaukos Investor Contact: Chris Lewis, Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clewis@glaukos.com Glaukos Media Contact: Cassandra Dump 619-971-1887 cassy@pascalecommunications.com Avedr
Read more →GKOSxA9; 2019 Glaukos Corporation 1
Disclaimer 5 2019 Glaukos Corporation Creating Hybrid Pharma & Device Ophthalmic Leader GLAUKOS TO ACQUIRE AVEDRO Combines two highly complementary, hybrid pharma & device ophthalmic organizations Leverages Glaukos' proven market-building experience, global commercial scale and s
Read more →GKOSgkos_Ex99_1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Second Quarter 2019 Financial Results
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Second Quarter 2019 Financial Results San Clemente, CA August 7, 2019 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel ther
Read more →GKOSgkos_Ex99_1 FOR IMMEDIATE RELEASE Media Contact: Cassandra Dump 619-971-1887 cassy@pascalecommunications.com Investor Contact: Chris Lewis, Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clew
cassy@pascalecommunications.com Chris Lewis, Director, Investor Relations, Corporate Development & Strategy Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation Early-Stage Bioerodible Sustained-Release Technologies Designed for the Treatme
Read more →GKOSxA9; 2019 Glaukos Corporation 1 May 2019 2 © 2019 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities, events or developments that we ex
Rx units sold $2.2B Est. annual revenue = 23 2019 Glaukos Corporation iDose Travoprost Procedure iDose Travoprost is an unapproved drug and limited by US law to investigational use 24 2019 Glaukos Corporation iDose Travoprost Exchange (Removal) Procedure iDose Travoprost is an un
Read more →GKOSgkos_Ex99_1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2019 Financial Results S
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces First Quarter 2019 Financial Results San Clemente, CA May 8, 2019 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the developmen
Read more →GKOSxA9; 2019 Glaukos Corporation 1 March 2019 2 © 2019 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities, events or developments that we
Rx units sold $2.2B Est. annual revenue = 23 2019 Glaukos Corporation iDose Travoprost Procedure iDose Travoprost is an unapproved drug and limited by US law to investigational use 24 2019 Glaukos Corporation iDose Travoprost Exchange (Removal) Procedure iDose Travoprost is an un
Read more →GKOSgkos_Ex99_1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Fina
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results San Clemente, CA February 27, 2019 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focu
Read more →GKOSxA9; 2019 Glaukos Corporation 1 January 2019 2 © 2019 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities, events or developments that w
Rx units sold $2.2B Est. annual revenue = 23 2019 Glaukos Corporation iDose Travoprost Procedure iDose Travoprost is an unapproved drug and limited by US law to investigational use 24 2019 Glaukos Corporation iDose Travoprost Exchange (Removal) Procedure iDose Travoprost is an un
Read more →GKOSxA9; 2018 Glaukos Corporation 1 November 2018 2 © 2018 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities, events or developments that
Western Development Agreement 29 2018 Glaukos Corporation Glaukos: Key Takeaways Delivering novel surgical and pharmaceutical glaucoma therapy - Validating iDoseTM drug delivery system and developing new sustained pharmaceuticals platform - Extending leadership in MIGS treatment
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2018 Financial Results San Clemente,
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Third Quarter 2018 Financial Results San Clemente, CA November 7, 2018 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the devel
Read more →GKOSSeptember 2018 1 © 2018 Glaukos Corporation 1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe
Western Therapeutics Institute to explore novel rho kinase (ROCK) inhibitor compounds Understanding necessary drug characteristics and predictability for delivery via iDoseTM system - - D. Western Development Agreement iDoseTM Travoprost - - - - - Small-molecule APIs, high potenc
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Second Quarter 2018 Financial Results San Clemente
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Second Quarter 2018 Financial Results San Clemente, CA August 2, 2018 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the develo
Read more →GKOSMay 2018 1 © 2018 Glaukos Corporation 1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or an
Single-Product Competitors Mild to Moderate Alcon CyPassTM - 6.35 mm polyimide shunt implanted ab interno into suprachoroidal space - Approved by FDA in 2016 for combo-cataract procedures Refractory Allergan XENTM 6 mm collagen shunt implanted ab interno into subconjunctival spac
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2018 Financial Results San Clemente,
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces First Quarter 2018 Financial Results San Clemente, CA May 9, 2018 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the developmen
Read more →GKOSCassandra Dump (619) 971-1887 cassy@pascalecommunications.com Investor Contact: Chris Lewis Director, Investor Relations, Corporate Development & Strategy (949) 481-0510 clewis@glauko
cassy@pascalecommunications.com Director, Investor Relations, Corporate Development & Strategy Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc. San Clemente, CA April 14, 2018 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on
Read more →GKOSMarch 2018 1 © 2018 Glaukos Corporation 1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or
Single-Product Competitors Mild to Moderate Alcon CyPass - 6.35 mm polyimide shunt implanted ab interno into suprachoroidal space - Approved by FDA in 2016 for combo-cataract procedures Refractory Allergan XEN 6 mm collagen shunt implanted ab interno into subconjunctival space Cr
Read more →GKOSChris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Result
Director, Investor Relations, Corporate Strategy & Development Glaukos Corporation Announces Fourth Quarter and Full Year 2017 San Clemente, CA February 28, 2018 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercial
Read more →GKOSGlaukos® Transforming Glaucoma Therpy January 2018 1 © 2018 Glaukos Corporation 1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, event
Single-Product Competitors Mild to Moderate Alcon CyPass - 6.35 mm polyimide shunt implanted ab interno into suprachoroidal space - Approved by FDA in 2016 for combo-cataract procedures Refractory Allergan XEN 6 mm collagen shunt implanted ab interno into subconjunctival space Cr
Read more →GKOSNovember 2017 1 © 2017 Glaukos Corporation 1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe
Normal IOP in healthy eyes ranges from 10-21 mm Hg. 1 Target IOP 20% from baseline; 18 mm Hg Treatment 0-1 med Open-Angle Glaucoma Progression Refractory OAG Uncontrolled IOP with severe optic nerve damage and visual field loss Mild OAG IOP of 25-30 mm Hg with minor optic nerve d
Read more →GKOSSheree Aronson VP, Investor Relations (949) 481-0361 saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2017 Financial Results San Clemente, CA –
VP, Investor Relations saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2017 Financial Results San Clemente, CA November 7, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of break
Read more →GKOSSheree Aronson VP, Investor Relations (949) 481-0361 saronson@glaukos.com Glaukos to Outline Growth Strategy at Investor Day Company Revises 2017 Net Sales Guidance San Clemente, CA –
VP, Investor Relations saronson@glaukos.com Glaukos to Outline Growth Strategy at Investor Day Company Revises 2017 Net Sales Guidance San Clemente, CA September 14, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and
Read more →GKOSAugust 2017 © 2017 Glaukos Corporation. 2 © 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or develop
Financial Summary NET SALESGROSS MARGIN 85.0% primarily by increases in trained 80.0%doctors and ASPs 75.0% manufacturing and cost structure Continued investments in pipeline global expansion 60.0% 20132014201520162017Q2 2016Q2 2017 87% 85% $114.4 $77.2 (1H 17) $71.7 $51.6 (1H 16
Read more →GKOSSheree Aronson VP, Investor Relations (949) 481-0361 saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2017 Financial Results San Clemente, CA –
VP, Investor Relations saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2017 Financial Results San Clemente, CA August 2, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakt
Read more →GKOSMay 2017 © 2017 Glaukos Corporation. 2 © 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developmen
Growth Strategies: Establishing MIGS as OAG Standard of Care 01020304 Increase US iStentSecure FDA approvalsDevelop, secureExtend global reach of adoption with seasonedwith expandedregulatory approval forMIGS-based platform sales force, broadindications for iStentand commercializ
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces First Quarter 2017 Financial Results Company Raises 2017 Net Sales Guidance S
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces First Quarter 2017 Financial Results Company Raises 2017 Net Sales Guidance San Clemente, CA May 3, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology compan
Read more →GKOSMarch 2017 2017 Glaukos Corporation. 2 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we e
March 2017 2017 Glaukos Corporation. 2 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the futur
Read more →GKOSAs of 02242017 FOR IMMEDIATE RELEASE Contact: Sheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Fourth Quarter & Full Year 2016 Financial Results Company Also
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Fourth Quarter & Full Year 2016 Financial Results Company Also Provides 2017 Net Sales Guidance San Clemente, CA March 1, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic me
Read more →GKOSCassandra Dump (619) 971-1887 cassy@pascalecommunications.com Investor Contact: Sheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com JOSEPH GILLIAM TO JOI
cassy@pascalecommunications.com VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com JOSEPH GILLIAM TO JOIN GLAUKOS CORPORATION AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT Former J.P. Morgan Healthcare Investment Banking Vetera
Read more →GKOSCassandra Dump (619) 971-1887 cassy@pascalecommunications.com Investor Contact: Sheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com GLAUKOS CORPORATION P
cassy@pascalecommunications.com VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com GLAUKOS CORPORATION PROMOTES CHRIS M. CALCATERRA TO CHIEF OPERATING OFFICER San Clemente, CA February 1, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology
Read more →GKOSJanuary 2017 2 DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in
In the United States, the iStent is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication. mm Hg 15.9 14.1 12.2 10 14 18 22 26 Mean preop med
Read more →GKOSGrowth Strategies: Establishing MIGS as OAG Standard of Care 01020304 Increase US iStentSecure FDA approvalsDevelop, secureExtend global reach of adoption with seasonedwith expande
Growth Strategies: Establishing MIGS as OAG Standard of Care 01020304 Increase US iStentSecure FDA approvalsDevelop, secureExtend global reach of adoption with seasonedwith expandedregulatory approval forMIGS-based platform sales force, broadindications for iStentand commercializ
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance S
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance San Clemente, CA November 10, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology
Read more →GKOSAugust 2016 2 DISCLAIMER All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in
2 DISCLAIMER All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements, including the company s revis
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance Laguna Hills, CA August 1, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology co
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Announces Planned Retirement of Chief Financial Officer Richard L. Harrison Laguna Hills, CA
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Announces Planned Retirement of Chief Financial Officer Richard L. Harrison Laguna Hills, CA July 14, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the dev
Read more →GKOSJune 2016 2016 Glaukos Corporation. 2 2016 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we ex
June 2016 2016 Glaukos Corporation. 2 2016 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces First Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance L
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces First Quarter 2016 Financial Results Company Raises 2016 Net Sales Guidance Laguna Hills, CA May 3, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology compan
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Announces Retirement of Olav Bergheim from Board of Directors Laguna Hills, CA
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Announces Retirement of Olav Bergheim from Board of Directors Laguna Hills, CA April 14, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and c
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Fourth Quarter & Full Year 2015 Financial Results Laguna Hills, CA
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Fourth Quarter & Full Year 2015 Financial Results Laguna Hills, CA March 1, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the develop
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Provides Preliminary Fourth Quarter and Full Year 2015 Net Sales and Full Year 2016 Net Sales Guida
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Provides Preliminary Fourth Quarter and Full Year 2015 Net Sales and Full Year 2016 Net Sales Guidance Laguna Hills, CA January 12, 2016 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technol
Read more →GKOSInvestor Presentation December 2-4, 2015 2 All statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future ar
Investor Presentation December 2-4, 2015 2 All statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we h
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2015 Financial Results Company Provides Revenue Guidance for 20
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Third Quarter 2015 Financial Results Company Provides Revenue Guidance for 2015 Laguna Hills, CA November 10, 2015 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technol
Read more →GKOSSheree Aronson VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2015 Financial Results Laguna Hills, CA
VP, Investor Relations (949) 367-9600 ext 371 saronson@glaukos.com Glaukos Corporation Announces Second Quarter 2015 Financial Results Laguna Hills, CA, August 12, 2015 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and c
Read more →Competitive Position
How GKOS ranks across every disease it competes inCompetitive Position is a premium feature
See how GKOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial